Recombinant human TGF beta 1 protein (Active)
Recombinant human TGF beta 1 protein (Active)
- Bioactive
- 了解详情
Be the first to review this product! Submit a review
|
(78 Publications)
Recombinant human TGF beta 1 protein (Active) is a Human Full Length TGF-beta 1 protein, in the 279 to 390 aa range with >98% purity, < 1 EU/µg endotoxin level and suitable for Cell Culture, Functional studies, western blot, HPLC and SDS-PAGE. The predicted molecular weight of ab50036 recombinant protein is 25 kDa.
- Save time and ensure accurate results - using our recombinant TGF-beta 1 cytokine protein
- Optimal protein bioactivity, stability and reproducibility
- Available in different sizes to fit your experimental needs
- Cited in over 60 publications
查看别名
TGFB, TGFB1, Transforming growth factor beta-1 proprotein
反应性数据
产品详情
Check out our Western blot protocol for more information here
TGF-beta is secreted predominantly as latent complexes which are stored at the cell surface and in the extracellular matrix.
The release of biologically active TGF-β isoform from a latent complex involves proteolytic processing of the complex and/or induction of conformational changes by proteins such as thrombospondin-1.
TGF-β1 is the most abundant isoform secreted by almost every cell type.
序列信息
性能和储存信息
运输条件
推荐的短期储存条件
推荐的长期储存条件
分装信息
储存信息
特殊说明
形式
Lyophilized
附加说明
> 98% by HPLC analyses. Endotoxin Level: < 0.1 ng/µg of protein (< 1 EU/µg).
常规信息
功能
Transforming growth factor beta-1 proprotein : Precursor of the Latency-associated peptide (LAP) and Transforming growth factor beta-1 (TGF-beta-1) chains, which constitute the regulatory and active subunit of TGF-beta-1, respectively.. Latency-associated peptide. Required to maintain the Transforming growth factor beta-1 (TGF-beta-1) chain in a latent state during storage in extracellular matrix (PubMed : 28117447). Associates non-covalently with TGF-beta-1 and regulates its activation via interaction with 'milieu molecules', such as LTBP1, LRRC32/GARP and LRRC33/NRROS, that control activation of TGF-beta-1 (PubMed : 19651619, PubMed : 19750484, PubMed : 2022183, PubMed : 22278742, PubMed : 8617200, PubMed : 8939931). Interaction with LRRC33/NRROS regulates activation of TGF-beta-1 in macrophages and microglia (Probable). Interaction with LRRC32/GARP controls activation of TGF-beta-1 on the surface of activated regulatory T-cells (Tregs) (PubMed : 19651619, PubMed : 19750484, PubMed : 22278742). Interaction with integrins (ITGAV : ITGB6 or ITGAV : ITGB8) results in distortion of the Latency-associated peptide chain and subsequent release of the active TGF-beta-1 (PubMed : 22278742, PubMed : 28117447).. Transforming growth factor beta-1. Multifunctional protein that regulates the growth and differentiation of various cell types and is involved in various processes, such as normal development, immune function, microglia function and responses to neurodegeneration (By similarity). Activation into mature form follows different steps : following cleavage of the proprotein in the Golgi apparatus, Latency-associated peptide (LAP) and Transforming growth factor beta-1 (TGF-beta-1) chains remain non-covalently linked rendering TGF-beta-1 inactive during storage in extracellular matrix (PubMed : 29109152). At the same time, LAP chain interacts with 'milieu molecules', such as LTBP1, LRRC32/GARP and LRRC33/NRROS that control activation of TGF-beta-1 and maintain it in a latent state during storage in extracellular milieus (PubMed : 19651619, PubMed : 19750484, PubMed : 2022183, PubMed : 22278742, PubMed : 8617200, PubMed : 8939931). TGF-beta-1 is released from LAP by integrins (ITGAV : ITGB6 or ITGAV : ITGB8) : integrin-binding to LAP stabilizes an alternative conformation of the LAP bowtie tail and results in distortion of the LAP chain and subsequent release of the active TGF-beta-1 (PubMed : 22278742, PubMed : 28117447). Once activated following release of LAP, TGF-beta-1 acts by binding to TGF-beta receptors (TGFBR1 and TGFBR2), which transduce signal (PubMed : 20207738). While expressed by many cells types, TGF-beta-1 only has a very localized range of action within cell environment thanks to fine regulation of its activation by Latency-associated peptide chain (LAP) and 'milieu molecules' (By similarity). Plays an important role in bone remodeling : acts as a potent stimulator of osteoblastic bone formation, causing chemotaxis, proliferation and differentiation in committed osteoblasts (By similarity). Can promote either T-helper 17 cells (Th17) or regulatory T-cells (Treg) lineage differentiation in a concentration-dependent manner (By similarity). At high concentrations, leads to FOXP3-mediated suppression of RORC and down-regulation of IL-17 expression, favoring Treg cell development (By similarity). At low concentrations in concert with IL-6 and IL-21, leads to expression of the IL-17 and IL-23 receptors, favoring differentiation to Th17 cells (By similarity). Stimulates sustained production of collagen through the activation of CREB3L1 by regulated intramembrane proteolysis (RIP) (PubMed : 25310401). Mediates SMAD2/3 activation by inducing its phosphorylation and subsequent translocation to the nucleus (PubMed : 25893292, PubMed : 29483653, PubMed : 30696809). Positively regulates odontoblastic differentiation in dental papilla cells, via promotion of IPO7-mediated translocation of phosphorylated SMAD2 to the nucleus and subsequent transcription of target genes (By similarity). Can induce epithelial-to-mesenchymal transition (EMT) and cell migration in various cell types (PubMed : 25893292, PubMed : 30696809).
序列相似性
Belongs to the TGF-beta family.
翻译后修饰
Transforming growth factor beta-1 proprotein: The precursor proprotein is cleaved in the Golgi apparatus by FURIN to form Transforming growth factor beta-1 (TGF-beta-1) and Latency-associated peptide (LAP) chains, which remain non-covalently linked, rendering TGF-beta-1 inactive.. Latency-associated peptide. N-glycosylated (PubMed:2493139, PubMed:28117447, PubMed:3162913). Deglycosylation leads to activation of Transforming growth factor beta-1 (TGF-beta-1); mechanisms triggering deglycosylation-driven activation of TGF-beta-1 are however unclear (PubMed:2493139).
靶点信息
文献 (78)
Recent publications for all applications. Explore the full list and refine your search
International journal of ophthalmology 18:779-791 PubMed40385123
2025
Applications
Unspecified application
Species
Unspecified reactive species
International journal of molecular sciences 26: PubMed40244247
2025
Applications
Unspecified application
Species
Unspecified reactive species
FASEB journal : official publication of the Federation of American Societies for Experimental Biology 39:e70427 PubMed40022609
2025
Applications
Unspecified application
Species
Unspecified reactive species
BMC pharmacology & toxicology 26:17 PubMed39871379
2025
Applications
Unspecified application
Species
Unspecified reactive species
Frontiers in neuroscience 18:1504047 PubMed39840011
2025
Applications
Unspecified application
Species
Unspecified reactive species
International journal of fertility & sterility 19:64-69 PubMed39827393
2025
Applications
Unspecified application
Species
Unspecified reactive species
Cancers 16: PubMed39518142
2024
Applications
Unspecified application
Species
Unspecified reactive species
Scientific data 11:868 PubMed39127790
2024
Applications
Unspecified application
Species
Unspecified reactive species
Journal for immunotherapy of cancer 12: PubMed38964786
2024
Applications
Unspecified application
Species
Unspecified reactive species
International journal of molecular sciences 25: PubMed38892298
2024
Applications
Unspecified application
Species
Unspecified reactive species
Abcam Product Promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com